ICHNO-ECHNO 2022 - Abstract Book

S79

ICHNO-ECHNO 2022

Conclusion Our study identified a sub-group of patients with clinically-evident ENE who may become ENE-negative due to the effects of NACT. Future research may be undertaken to identify if concurrent chemotherapy can be avoided in these patients when they receive radiotherapy, and a randomized clinical trial may be designed for the same.

PO-0126 Acute kidney impairment in high dose cisplatin-treated head and neck cancer: a new perspective.

A. Mirabile 1 , F. Trevisani 2 , G. Quattrini 2 , L. Giordano 3 , A. Galli 4 , I. Dell'oca 5 , C. Deantoni 5 , D. Valsecchi 6 , A. Cinque 7 , V. Gregorc 1 1 IRCCS Ospedale San Raffaele, Medical Oncology Department, Milan, Italy; 2 IRCCS Ospedale San Raffaele, Urology, Milan, Italy; 3 IRCCS Ospedale San Raffaele, Otolaringology-Head and neck surgery, Milan, Italy; 4 IRCCS Ospedale San Raffaele, Otolaryngology-head and neck surgery, Milan, Italy; 5 IRCCS Ospedale San Raffaele, Radiotherapy department, Milan, Italy; 6 IRCCS Ospedale San Raffaele, Emergency Department, Milan, Italy; 7 IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy Purpose or Objective Three-weekly high-dose cisplatin (100 mg/m 2 ) represents the standard of care given in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Increasingly, low-dose once-a-week cisplatin is substituted because of perceived lower renal toxicity. However, there is no level 1 evidence of comparable efficacy to cisplatin once-a-week and every 3 weeks. Aim of this study was to investigate the incidence of AKI in patients with LA-SCCHN during and after treatment with high-dose cisplatin-based CRT to identify risk factors for cisplatin-induced AKI. Materials and Methods A consecutive cohort of 93 patients, with a basal normal serum creatinine level, treated with high dose cisplatin ( ³ 200mg/m2 total), were enrolled in a tertiary single Hospital between 2019 and 2021. Serum creatinine and eGFR formulas (CKD-EPI, MDRD, Cockcroft-Gault) were detected at baseline and after each cycle of chemotherapy. AKI and CKD onset were determined according to K-DIGO criteria. Tumor clinical stage as well as comorbidities were also included. Bayesian linear regression was used to evaluate the impact of the clinical and pathological features on eGFR decay through cycles.

Results